Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:AFMD

Affimed - AFMD Stock Forecast, Price & News

$2.04
-0.05 (-2.39%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.01
$2.15
50-Day Range
$1.48
$2.45
52-Week Range
$1.40
$7.13
Volume
1.89 million shs
Average Volume
1.44 million shs
Market Capitalization
$251.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Affimed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
267.6% Upside
$7.50 Price Target
Short Interest
Healthy
3.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.13mentions of Affimed in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.61) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

510th out of 1,040 stocks

Pharmaceutical Preparations Industry

244th out of 509 stocks

AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

Why Shares of Affimed Fell Thursday
Affimed Third Quarter 2022 Earnings: Beats Expectations
Why Affimed Stock Plummeted by Over 16% Today
Affimed N.V. (AFMD)
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+267.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-68,060,000.00
Net Margins
-189.04%
Pretax Margin
-190.34%

Debt

Sales & Book Value

Annual Sales
$47.76 million
Book Value
$1.30 per share

Miscellaneous

Free Float
N/A
Market Cap
$251.78 million
Optionable
Optionable
Beta
2.19

Key Executives

  • Dr. Adi Hoess (Age 61)
    CEO, MD & Member of Management Board
    Comp: $771.95k
  • Mr. Angus W. Smith (Age 40)
    CFO & Member of Management Board
    Comp: $556.04k
  • Dr. Wolfgang Fischer (Age 58)
    MD, COO & Member of Management Board
    Comp: $608.29k
  • Ms. Denise Mueller (Age 53)
    Chief Bus. Officer & Member of Management Board
    Comp: $530.41k
  • Dr. Andreas Harstrick M.D. (Age 61)
    Chief Medical Officer & Member of Management Board
    Comp: $504.77k
  • Dr. Arndt J. G. Schottelius M.D. (Age 56)
    Ph.D., Chief Scientific Officer & Member of Management Board
    Comp: $610.26k
  • Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael Wolf (Age 55)
    Head of Fin. & Admin.
  • Mr. Alexander Fudukidis
    Head of Investor Relations
  • Dr. Uwe Reusch
    Head of Cell Culture













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2023?

5 analysts have issued 1 year price targets for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 258.9% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2022?

Affimed's stock was trading at $5.52 on January 1st, 2022. Since then, AFMD shares have decreased by 62.1% and is now trading at $2.09.
View the best growth stocks for 2022 here
.

Are investors shorting Affimed?

Affimed saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,900,000 shares, a decrease of 8.2% from the October 31st total of 4,250,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 2.4 days.
View Affimed's Short Interest
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 48.46% and a negative net margin of 189.04%. During the same quarter in the previous year, the business posted ($0.08) EPS.

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by many different institutional and retail investors. Top institutional investors include 683 Capital Management LLC (6.77%), BlackRock Inc. (6.27%), Point72 Asset Management L.P. (4.36%), State Street Corp (1.91%), Stonepine Capital Management LLC (1.60%) and Vanguard Group Inc. (1.13%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.09.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $257.95 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Affimed have?

The company employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 11/28/2022 by MarketBeat.com Staff